Status:
RECRUITING
Biomarkers in Patients With Suspected HFpEF
Lead Sponsor:
NHS Greater Glasgow and Clyde
Collaborating Sponsors:
University of Glasgow
Roche Diagnostics GmbH
Conditions:
Heart Failure
Obesity
Eligibility:
All Genders
18+ years
Brief Summary
NT-proBNP does not adequately identify HF(pEF) in people with suspected HF at low levels, particularly in patients with obesity. This study will investigate: 1. alternative cut-offs for NT-proBNP to ...
Detailed Description
This will be a prospective observational, non-randomised study of patients in primary care with suspected HF. Detection of HFpEF in people without obesity is well-served by NT-proBNP. In contrast, NT...
Eligibility Criteria
Inclusion
- Written informed consent
- Age ≥ 18 years
- NT-proBNP sample taken by primary care physician as part of routine care for suspected heart failure
Exclusion
- Unable to consent to inclusion in study due to significant cognitive impairment
- Geographical/ social reasons preventing attending study centre
- Unable to complete study assessments
- Patients presenting with acute HF or a previous diagnosis of HF
Key Trial Info
Start Date :
February 2 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 29 2026
Estimated Enrollment :
1028 Patients enrolled
Trial Details
Trial ID
NCT06101693
Start Date
February 2 2023
End Date
September 29 2026
Last Update
February 13 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Glasgow Royal Infirmary
Glasgow, United Kingdom, G128TA
2
New Victoria Hospital
Glasgow, United Kingdom, G51 4TF
3
Queen Elizabeth University Hospital
Glasgow, United Kingdom, G51 4TF